Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CLDX – Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.
CLDX
$25.94
Name : Celldex Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,723,699,328.00
EPSttm : -3.38
finviz dynamic chart for CLDX
Celldex Therapeutics, Inc.
$25.94
1.53%
$0.39

Float Short %

11.63

Margin Of Safety %

Put/Call OI Ratio

1.01

EPS Next Q Diff

-0.02

EPS Last/This Y

-1.1

EPS This/Next Y

-0.81

Price

25.56

Target Price

53.14

Analyst Recom

1.5

Performance Q

4.37

Relative Volume

0.81

Beta

1.16

Ticker: CLDX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20CLDX27.670.900.655188
2025-10-21CLDX27.910.900.015213
2025-10-22CLDX26.720.870.865308
2025-10-23CLDX26.260.870.005319
2025-10-24CLDX26.740.870.005320
2025-10-27CLDX27.390.875.675321
2025-10-28CLDX27.070.86217.505317
2025-10-29CLDX25.990.890.915382
2025-10-30CLDX25.990.890.275385
2025-10-31CLDX26.710.89999.995390
2025-11-03CLDX24.630.9013.585400
2025-11-04CLDX23.970.9530.005568
2025-11-05CLDX23.721.002.145708
2025-11-06CLDX23.251.000.035710
2025-11-07CLDX22.91.000.235717
2025-11-10CLDX22.671.000.335715
2025-11-11CLDX24.361.000.205719
2025-11-12CLDX24.261.015.005713
2025-11-13CLDX23.721.010.605717
2025-11-14CLDX25.421.010.035720
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20CLDX27.67-39.5-90.8-3.42
2025-10-21CLDX27.92-39.5-80.1-3.42
2025-10-22CLDX26.72-39.5-55.8-3.42
2025-10-23CLDX26.26-39.5-67.6-3.42
2025-10-24CLDX26.74-39.5-84.6-3.42
2025-10-27CLDX27.38-39.5-87.6-3.42
2025-10-28CLDX27.06-39.5-70.4-3.42
2025-10-29CLDX25.95-39.5-56.1-3.42
2025-10-30CLDX26.00-39.5-75.9-3.42
2025-10-31CLDX26.73-39.5-89.5-3.42
2025-11-03CLDX24.73-39.5-39.7-3.42
2025-11-04CLDX23.83-39.5-57.0-3.42
2025-11-05CLDX23.72-39.5-72.9-3.42
2025-11-06CLDX23.26-39.5-65.5-3.42
2025-11-07CLDX22.90-39.5-67.7-3.42
2025-11-10CLDX22.67-39.5-70.4-3.42
2025-11-11CLDX24.37-39.5-115.7-3.42
2025-11-12CLDX24.24-39.5-51.9-3.42
2025-11-13CLDX23.71-37.6-43.5-3.42
2025-11-14CLDX25.56-37.6-92.2-3.55
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20CLDX-0.04-1.4910.98
2025-10-21CLDX-0.04-1.4910.98
2025-10-22CLDX-0.04-1.4910.98
2025-10-23CLDX-0.04-1.4910.98
2025-10-24CLDX-0.04-1.4910.98
2025-10-27CLDX-0.04-1.6711.46
2025-10-28CLDX-0.04-1.6711.46
2025-10-29CLDX-0.04-1.6711.46
2025-10-30CLDX-0.04-1.6711.46
2025-10-31CLDX-0.04-1.6711.46
2025-11-03CLDX-0.04-1.6011.46
2025-11-04CLDX-0.04-1.6011.46
2025-11-05CLDX-0.04-1.6011.46
2025-11-06CLDX-0.04-1.6011.46
2025-11-07CLDX-0.04-1.6011.46
2025-11-10CLDX-0.04-1.6911.46
2025-11-11CLDX-0.04-1.6911.46
2025-11-12CLDX-0.04-1.6911.64
2025-11-13CLDX-0.04-1.6911.63
2025-11-14CLDX-0.04-1.6911.63
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.01

Avg. EPS Est. Current Quarter

-0.98

Avg. EPS Est. Next Quarter

-1.03

Insider Transactions

-0.04

Institutional Transactions

-1.69

Beta

1.16

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

Fair Value

Quality Score

20

Growth Score

35

Sentiment Score

41

Actual DrawDown %

55.3

Max Drawdown 5-Year %

-73.1

Target Price

53.14

P/E

Forward P/E

PEG

P/S

652.99

P/B

2.84

P/Free Cash Flow

EPS

-3.38

Average EPS Est. Cur. Y​

-3.55

EPS Next Y. (Est.)

-4.36

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-8635.85

Relative Volume

0.81

Return on Equity vs Sector %

-64.4

Return on Equity vs Industry %

-49.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.13

EBIT Estimation

-92.2
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 186
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading